Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of satralizumab in moderate-to-severe thyroid eye disease
MOH_2024-03-04_012998Phase 3Not yet recruiting
- Sponsor
- Roche
- Start
- Feb 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Graves Orbitopathy (GO) comparing Satralizumab with Placebo (2 arms). Primary endpoint: Primary endpoint not reported. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
satralizumab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on MOH_2024-03-04_012998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-03-04_012998.